BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 276 filers reported holding BIO-TECHNE CORP in Q2 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,328,716 | -16.6% | 254,572 | +0.0% | 0.30% | -9.7% |
Q2 2023 | $20,775,406 | +8.1% | 254,507 | -1.8% | 0.33% | +2.5% |
Q1 2023 | $19,219,290 | -10.6% | 259,055 | -0.1% | 0.32% | -19.9% |
Q4 2022 | $21,497,000 | +15.5% | 259,375 | +295.9% | 0.40% | +10.4% |
Q3 2022 | $18,606,000 | -16.7% | 65,515 | +1.7% | 0.36% | -10.3% |
Q2 2022 | $22,330,000 | -20.4% | 64,419 | -0.6% | 0.41% | -4.0% |
Q1 2022 | $28,069,000 | -16.2% | 64,819 | +0.1% | 0.42% | -3.0% |
Q4 2021 | $33,495,000 | -8.1% | 64,744 | -13.9% | 0.44% | -13.5% |
Q3 2021 | $36,434,000 | +8.8% | 75,189 | +1.1% | 0.50% | +4.1% |
Q2 2021 | $33,474,000 | +28.6% | 74,343 | +9.1% | 0.48% | +23.5% |
Q1 2021 | $26,035,000 | -65.8% | 68,168 | -71.6% | 0.39% | -67.7% |
Q4 2020 | $76,135,000 | -20.2% | 239,757 | -37.7% | 1.21% | -37.0% |
Q3 2020 | $95,389,000 | -0.5% | 385,051 | +6.0% | 1.92% | -7.9% |
Q2 2020 | $95,885,000 | +44.0% | 363,104 | +3.4% | 2.09% | +7.2% |
Q1 2020 | $66,581,000 | -5.7% | 351,128 | +9.2% | 1.95% | +14.7% |
Q4 2019 | $70,601,000 | +11.0% | 321,632 | -1.0% | 1.70% | +4.4% |
Q3 2019 | $63,593,000 | -7.2% | 324,999 | -1.1% | 1.63% | -5.0% |
Q2 2019 | $68,506,000 | +7.4% | 328,584 | +2.3% | 1.71% | -3.6% |
Q1 2019 | $63,800,000 | +38.1% | 321,328 | +0.6% | 1.78% | +20.7% |
Q4 2018 | $46,206,000 | -26.8% | 319,277 | +3.2% | 1.47% | -8.6% |
Q3 2018 | $63,128,000 | +56.7% | 309,282 | +13.6% | 1.61% | +24.2% |
Q2 2018 | $40,297,000 | +2.3% | 272,367 | +4.4% | 1.30% | -14.0% |
Q1 2018 | $39,387,000 | +10.6% | 260,772 | -5.1% | 1.51% | +10.3% |
Q4 2017 | $35,603,000 | +19.4% | 274,822 | +11.5% | 1.37% | +3.6% |
Q3 2017 | $29,809,000 | -7.0% | 246,582 | -9.6% | 1.32% | -20.9% |
Q2 2017 | $32,057,000 | +23.1% | 272,828 | +6.5% | 1.67% | +6.0% |
Q1 2017 | $26,044,000 | +47.6% | 256,213 | +49.3% | 1.57% | +34.0% |
Q4 2016 | $17,650,000 | -5.6% | 171,644 | +0.5% | 1.18% | -8.3% |
Q3 2016 | $18,696,000 | +7.5% | 170,744 | +10.7% | 1.28% | -0.3% |
Q2 2016 | $17,395,000 | +3.7% | 154,249 | -13.1% | 1.28% | +13.3% |
Q1 2016 | $16,781,000 | +27.9% | 177,544 | +21.8% | 1.13% | +7.0% |
Q4 2015 | $13,116,000 | -10.4% | 145,735 | -8.0% | 1.06% | -9.7% |
Q3 2015 | $14,643,000 | -8.3% | 158,369 | -2.3% | 1.17% | +6.0% |
Q2 2015 | $15,964,000 | -2.4% | 162,120 | -0.6% | 1.11% | -1.1% |
Q1 2015 | $16,357,000 | +5.9% | 163,099 | -2.4% | 1.12% | +4.3% |
Q4 2014 | $15,440,000 | – | 167,095 | – | 1.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |